An essay on the history of civil society.

Mode of access: Internet.

Geodetic operations in the United States and in other areas through international cooperation, January 1, 1963 to December 31, 1966.

Mode of access: Internet.

Geodetic operations in the United States and in other areas through international cooperation, January 1, 1960 to December 31, 1962.

Mode of access: Internet.

Commentaries on the laws of the ancient Hebrews : with an introductory essay on civil society and government /

Mode of access: Internet.

The relation of Christianity to civil society,

Mode of access: Internet.

The railway foreman and his job, especially prepared for the education and training of railway foremen by the staff of the American Technical Society in cooperation with a group of railway executives.

Mode of access: Internet.

Iraq transition : civil war or civil society? : hearing before the Committee on Foreign Relations, United States Senate, One Hundred Eighth Congress, second session, April 20, 2004.

"April 22, 2004"--Pt. 3.

Terminal report [to the International Cooperation Administration] on the contract concerning public administration in the University of San Andrés.

Mode of access: Internet.

International cooperation and competition in civilian space activities : summary

"OTA-ISC-240"--P. [36]

International cooperation and competition in civilian space activities.

Item 1070-M.

OMERACT-OARSI Initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited.

Background: The OARSI Standing Committee for Clinical Trials Response Criteria Initiative had developed two sets of responder criteria to present the results of changes after treatment in three symptomatic domains (pain, function, and patient's global assessment) as a single variable for clinical trials (1). For each domain, a response was defined by both a relative and an absolute change, with different cut-offs with regard to the drug, the route of administration and the OA localization. Objective: To propose a simplified set of responder criteria with a similar cut-off, whatever the drug, the route or the OA localization. Methods: Data driven approach: (1) Two databases were considered The 'elaboration' database with which the formal OARSI sets of responder criteria were elaborated and The 'revisit' database. (2) Six different scenarios were evaluated: The two formal OARSI sets of criteria Four proposed scenarios of simplified sets of criteria Data from clinical randomized blinded placebo controlled trials were used to evaluate the performances of the two formal scenarios with two different databases ('elaboration' versus 'revisit') and those of the four proposed simplified scenarios within the 'revisit' database. The placebo effect, active effect, treatment effect, and the required sample arm size to obtain the placebo effect and the active treatment effect observed were the performances evaluated for each of the six scenarios. Experts' opinion approach: Results were discussed among the participants of the OMERACT VI meeting, who voted to select the definite OMERACT-OARSI set of criteria (one of the six evaluated scenarios). Results: Data driven approach: Fourteen trials totaling 1886 CA patients and fifteen studies involving 8164 CA patients were evaluated in the 'elaboration' and the 'revisit' databases respectively. The variability of the performances observed in the 'revisit' database when using the different simplified scenarios was similar to that observed between the two databases ('elaboration' versus 'revisit') when using the formal scenarios. The treatment effect and the required sample arm size were similar for each set of criteria. Experts' opinion approach: According to the experts, these two previous performances were the most important of an optimal set of responder criteria. They chose the set of criteria considering both pain and function as evaluation domain and requiring an absolute change and a relative change from baseline to define a response, with similar cut-offs whatever the drug, the route of administration or the CA localization. Conclusion: This data driven and experts' opinion approach is the basis for proposing an optimal simplified set of responder criteria for CA clinical trials. Other studies, using other sets of CA patients, are required in order to further validate this proposed OMERACT - OARSI set of criteria. (C) 2004 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.